Results 141 to 150 of about 40,760 (162)

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

Lancet, The, 2007
Kiat Ruxrungtham
exaly  

Ritonavir

2022
openaire   +1 more source

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

Lancet, The, 2006
Sharon L Walmsley, Bonaventura Clotet, Adriano Lazzarin   +2 more
exaly  

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Lancet, The, 2007
Bonaventura Clotet, Jean-Christophe Goffard, Adriano Lazzarin   +2 more
exaly  

Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

New England Journal of Medicine, 2002
Sharon L Walmsley
exaly  

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

Lancet, The, 2015
Tarik Asselah, K Rajender Reddy, Marina Berenguer   +2 more
exaly  

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Lancet, The, 2014
Bonaventura Clotet, Judith Feinberg, Andrea Antinori   +2 more
exaly  

A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection

New England Journal of Medicine, 1995
William G Powderly
exaly  

A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease

New England Journal of Medicine, 1995
Emilio Bouza, Rafael Delgado
exaly  

Extended pre-exposure prophylaxis with lopinavir–ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial

Lancet, The, 2016
Nicolas Nagot, Roselyne Vallo, Grace Ndeezi   +2 more
exaly